二肽基肽酶-4抑制剂致大疱性类天疱疮国内外文献分析

发布时间：2018-04-05 06:59

本文选题：二肽基肽酶-抑制剂　切入点：大疱性类天疱疮　出处：《中国新药杂志》2017年18期

【摘要】：目的:分析二肽基肽酶-4抑制剂致大疱性类天疱疮的发生规律及特点,为安全用药提供参考。方法:检索中国学术期刊全文数据库、维普中文科技期刊数据库、万方数据库和Pubmed数据库收载的二肽基肽酶-4抑制剂致大疱性类天疱疮文献并进行分析。结果:21例不良反应中,男性11例,女性10例,年龄60岁及以上患者20例(95.2%)。21例患者中,服用维格列汀者15例,服用西格列汀者3例,服用利拉列汀者3例。用药至发生大疱性类天疱疮的时间为1~37个月,平均时间8个月。结论:临床医师应了解二肽基肽酶-4抑制剂致大疱性类天疱疮的规律和特点,加强用药监测,以便及时发现和处理大疱性类天疱疮。
[Abstract]:Objective: to analyze the occurrence and characteristics of bullous pemphigoid induced by dipeptidyl peptidase-4 inhibitor.Methods: the full text database of Chinese academic journals, the database of Chinese science and technology journals, the database of Wanfang and the database of Pubmed were searched and analyzed in the literature of bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitor.Results of 21 cases, 11 cases were male, 10 cases were female, 20 cases were aged 60 years and above, 15 cases were treated with vigllline, 3 cases were treated with siglitatin, and 3 cases were treated with riparutin.The time from medication to bullous pemphigoid was 1 ~ 37 months, with an average time of 8 months.Conclusion: clinicians should understand the regularity and characteristics of bullous pemphigoid induced by dipeptidyl peptidase 4 inhibitor and strengthen drug monitoring in order to detect and treat bullous pemphigoid in time.
【作者单位】：安徽省蚌埠市第三人民医院药学部;
【分类号】：R977.15

【相似文献】